Cancer- and Chemotherapy-Induced Anemia

Authors:
George M. Rodgers III
Search for other papers by George M. Rodgers III in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Pamela Sue Becker
Search for other papers by Pamela Sue Becker in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Morey Blinder
Search for other papers by Morey Blinder in
Current site
Google Scholar
PubMed Close
 MD
,
David Cella
Search for other papers by David Cella in
Current site
Google Scholar
PubMed Close
 PhD
,
Asher Chanan-Khan
Search for other papers by Asher Chanan-Khan in
Current site
Google Scholar
PubMed Close
 MD
,
Charles Cleeland
Search for other papers by Charles Cleeland in
Current site
Google Scholar
PubMed Close
 PhD
,
Peter F. Coccia
Search for other papers by Peter F. Coccia in
Current site
Google Scholar
PubMed Close
 MD
,
Benjamin Djulbegovic
Search for other papers by Benjamin Djulbegovic in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Jeffrey A. Gilreath
Search for other papers by Jeffrey A. Gilreath in
Current site
Google Scholar
PubMed Close
 PharmD
,
Eric H. Kraut
Search for other papers by Eric H. Kraut in
Current site
Google Scholar
PubMed Close
 MD
,
Ursula A. Matulonis
Search for other papers by Ursula A. Matulonis in
Current site
Google Scholar
PubMed Close
 MD
,
Michael M. Millenson
Search for other papers by Michael M. Millenson in
Current site
Google Scholar
PubMed Close
 MD
,
Denise Reinke
Search for other papers by Denise Reinke in
Current site
Google Scholar
PubMed Close
 MS, NP
,
Joseph Rosenthal
Search for other papers by Joseph Rosenthal in
Current site
Google Scholar
PubMed Close
 MD
,
Rowena N. Schwartz
Search for other papers by Rowena N. Schwartz in
Current site
Google Scholar
PubMed Close
 PharmD
,
Gerald Soff
Search for other papers by Gerald Soff in
Current site
Google Scholar
PubMed Close
 MD
,
Richard S. Stein
Search for other papers by Richard S. Stein in
Current site
Google Scholar
PubMed Close
 MD
,
Gordana Vlahovic
Search for other papers by Gordana Vlahovic in
Current site
Google Scholar
PubMed Close
 MD
, and
Alva B. Weir III
Search for other papers by Alva B. Weir III in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 10: Issue 5
Online Publication Date:
May 2012
DOI:
https://doi.org/10.6004/jnccn.2012.0064
Restricted access

Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health effects of ESAs sparked a series of FDA label revisions and a sea change in the perception of these once commonly used agents. In light of this, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer- and Chemotherapy-Induced Anemia underwent substantial revisions this year. The purpose of these NCCN Guidelines is twofold: 1) to operationalize the evaluation and treatment of anemia in adult cancer patients, with an emphasis on those who are receiving concomitant chemotherapy, and 2) to enable patients and clinicians to individualize anemia treatment options based on patient condition.

  • Collapse
  • Expand
  • 1

    Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116(Suppl 7A):11S–26S.

  • 2

    Schwartz RN. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm 2007;64:S5–13; quiz S28–30.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    Steensma DP. Is anemia of cancer different from chemotherapy-induced anemia? J Clin Oncol 2008;26:1022–1024.

  • 4

    Wilson J, Yao GL, Raftery J et al.. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11:1–202, iii–iv.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5

    Moullet I, Salles G, Ketterer N et al.. Frequency and significance of anemia in non-Hodgkin’s lymphoma patients. Ann Oncol 1998;9:1109–1115.

  • 6

    Ludwig H, Van Belle S, Barrett-Lee P et al.. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293–2306.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616–1634.

  • 8

    Jefferies S, Rajan B, Ashley S et al.. Haematological toxicity of cranio-spinal irradiation. Radiother Oncol 1998;48:23–27.

  • 9

    Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 1996;4:82–96.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Miller Y, Bachowski G, Benjamin R et al.. Practice guidelines for blood transfusion: a compilation from recent peer-reviewed literature, 2nd edition. Washington, DC; American Red Cross; 2007. Available at: http://www.redcross.org/www-files/Documents/WorkingWiththeRedCross/practiceguidelinesforbloodtrans.pdf. Accessed April 1, 2012.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11

    Wiesen AR, Hospenthal DR, Byrd JC et al.. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann Intern Med 1994;121:278–230.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12

    Kader AS, Lim JT, Berthelet E et al.. Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy. Am J Clin Oncol 2007;30:492–497.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Spivak JL, Gascon P, Ludwig H. Anemia management in oncology and hematology. Oncologist 2009;14(Suppl 1):43–56.

  • 14

    Hill SR, Carless PA, Henry DA et al.. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2002:CD002042.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15

    Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med 2006;355:1303–1305.

  • 16

    King KE, Shirey RS, Thoman SK et al.. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004;44:25–29.

  • 17

    Yazer MH, Podlosky L, Clarke G, Nahirniak SM. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004;44:10–15.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18

    Khorana AA, Francis CW, Blumberg N et al.. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168:2377–2381.

  • 19

    Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089–1095.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20

    Vekeman F, Bookhart BK, White J et al.. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion 2009;49:895–902.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21

    Pawson R, Brunskill S, Murphy MF et al.. Different threshold levels for red blood cell transfusions in patients with haematological malignancy (Protocol). Cochrane Database Syst Rev 2006;3:CD006166.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22

    Hebert PC, Wells G, Blajchman MA et al.. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409–417.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23

    Steinbrook R. Erythropoietin, the FDA, and oncology. N Engl J Med 2007;356:2448–2451.

  • 24

    Littlewood TJ, Bajetta E, Nortier JW et al.. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–2874.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25

    Vansteenkiste J, Pirker R, Massuti B et al.. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211–1220.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26

    Bohlius J, Wilson J, Seidenfeld J et al.. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708–714.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27

    Food and Drug Administration. Epoetin alfa label. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103234Orig1s5166_103234Orig1s5266lbl.pdf. Accessed January 25, 2012.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28

    Food and Drug Administration. Darbepoetin alfa label. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103951Orig1s5173_103951Orig1s5258lbl.pdf. Accessed January 25, 2012.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29

    Untch M, Fasching PA, Bauerfeind I et al.. PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel {+/-} darbepoetin alfa in primary breast cancer: a preplanned interim analysis of efficacy at surgery [abstract]. J Clin Oncol 2008;26(Suppl 15):Abstract 517.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30

    Hedenus M, Adriansson M, San Miguel J et al.. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394–403.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31

    Henke M, Laszig R, Rube C et al.. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255–1260.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32

    Leyland-Jones B, Semiglazov V, Pawlicki M et al.. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960–5972.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33

    Overgaard J, Hoff CM, Hansen HS et al.. Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): final outcome of the DAHANCA 10 trial [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstract 6007.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34

    Smith RE Jr, Aapro MS, Ludwig H et al.. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040–1050.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35

    Thomas G, Ali S, Hoebers FJ et al.. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108:317–325.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36

    Wright JR, Ung YC, Julian JA et al.. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027–1032.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37

    Bennett CL, Silver SM, Djulbegovic B et al.. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914–924.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38

    Bohlius J, Schmidlin K, Brillant C et al.. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532–1542.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39

    Tonelli M, Hemmelgarn B, Reiman T et al.. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E62–71.

  • 40

    Bennett CL, Henke M, Lai SY. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia - reply. JAMA 2008;300:2855–2857.

  • 41

    Ludwig H, Crawford J, Osterborg A et al.. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27:2838–2847.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42

    Glaspy J, Crawford J, Vansteenkiste J et al.. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301–315.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43

    Engert A, Josting A, Haverkamp H et al.. Epoetin alfa in patients with advanced-stage Hodgkin’s lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010;28:2239–2245.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44

    Moebus V, Jackisch C, Lueck HJ et al.. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010;28:2874–2880.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45

    Untch M, Fasching PA, Konecny GE et al.. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel {+/-} darbepoetin alfa in primary breast cancer: results at the time of surgery. Ann Oncol 2011;22:1988–1998.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46

    Pirker R, Ramlau RA, Schuette W et al.. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008;26:2342–2349.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47

    Grote T, Yeilding AL, Castillo R et al.. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005;23:9377–9386.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48

    Heit JA, Silverstein MD, Mohr DN et al.. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809–815.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49

    Khorana AA, Francis CW, Culakova E et al.. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632–634.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50

    Levine MN, Gent M, Hirsh J et al.. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404–407.

  • 51

    Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286–294.

  • 52

    Lyman GH, Khorana AA, Falanga A et al.. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490–5505.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53

    Glaspy J, Osterborg A, Ludwig H et al.. Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin [abstract]. Eur J Cancer Suppl 2007;5:Abstract 147.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54

    Pfeffer MA, Burdmann EA, Chen CY et al.. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019–2032.

  • 55

    Food and Drug Administration. FDA information on ESAs. 2010. Available at: http://www.fda.gov/cder/drug/infopage/RHE/. Accessed January 25, 2012.

  • 56

    Bennett CL, Cournoyer D, Carson KR et al.. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005;106:3343–3347.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57

    Bennett CL, Luminari S, Nissenson AR et al.. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403–1408.

  • 58

    McKoy JM, Stonecash RE, Cournoyer D et al.. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008;48:1754–1762.

  • 59

    Food and Drug Administration. FDA on ESA-associated PRCA. 2006. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/printer.cfm?id=430. Accessed January 25, 2012.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60

    Bennett CL, Becker PS, Kraut EH et al.. Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Semin Dial 2009;22:1–4.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61

    Ballen KK, Becker PS, Yeap BY et al.. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 2004;22:4087–4094.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62

    Ballen KK, Ford PA, Waitkus H et al.. Successful autologous bone marrow transplant without the use of blood product support. Bone Marrow Transplant 2000;26:227–229.

  • 63

    Brown NM, Kim SY, Ford PA. Autologous stem cell transplants in Jehovah’s Witnesses. Bone Marrow Transplant 2009;44:391–392.

  • 64

    Glaspy J, Bukowski R, Steinberg D et al.. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218–1234.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65

    Gabrilove JL, Cleeland CS, Livingston RB et al.. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875–2882.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66

    Henry DH, Gordan LN, Charu V et al.. Randomized, open-label comparison of epoetin alfa extended dosing (80,000 U Q2W) vs weekly dosing (40,000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin 2006;22:1403–1413.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67

    Steensma DP, Molina R, Sloan JA et al.. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 2006;24:1079–1089.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68

    Canon JL, Vansteenkiste J, Bodoky G et al.. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273–284.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69

    Thames WA, Smith SL, Scheifele AC et al.. Evaluation of the US Oncology Network’s recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naive patients and patients switched from epoetin alfa. Pharmacotherapy 2004;24:313–323.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70

    Boccia R, Malik IA, Raja V et al.. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 2006;11:409–417.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71

    Henry DH. Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 1998;3:275–278.

  • 72

    Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011–1023.

  • 73

    Silverstein SB, Gilreath JA, Rodgers GM. Intravenous iron therapy: a summary of treatment options and review of guidelines. J Pharm Pract 2008;21:431–443.

  • 74

    Auerbach M, Ballard H, Trout JR et al.. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301–1307.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75

    Bastit L, Vandebroek A, Altintas S et al.. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611–1618.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76

    Hedenus M, Birgegard G, Nasman P et al.. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627–632.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77

    Henry DH, Dahl NV, Auerbach M et al.. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231–242.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78

    Pedrazzoli P, Farris A, Del Prete S et al.. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619–1625.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79

    Steensma DP, Sloan JA, Dakhil SR et al.. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011;29:97–105.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80

    Mhaskar R, Wao H, Kumar A et al.. Role of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patients: a systematic review and meta-analysis [abstract]. Blood 2010;116(Suppl 21):Abstract 2055.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81

    National Institutes of Health. Ferrlecit package insert. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2f2f298-2dec-4020-97c8-2aade4b99b2e. Accessed January 25, 2012.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82

    National Institutes of Health. Venofer package insert. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=626dc9e5-c6b4-4f9c-9bf4-774fd3ae619a. Accessed January 25, 2012.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83

    Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004;76:74–78.

  • 84

    Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378–382.

  • 85

    Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007;369:1502–1504.

  • 86

    Lapointe M. Iron supplementation in the intensive care unit: when, how much, and by what route? Crit Care 2004;8(Suppl 2):S37–41.

Copyright:
Copyright © 2012 by the National Comprehensive Cancer Network 2012
Page Numbers:
26
Article Category:
Research Article
Print Publication Date:
01 May 2012
Online Publication Date:
May 2012
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 11778 2832 358
PDF Downloads 7057 2315 184
EPUB Downloads 0 0 0